LMP-744 is under clinical development by Gibson Oncology and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect LMP-744’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their LMP-744 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
LMP-744 is under development for the treatment of relapsed solid tumors and lymphomas. It is administered through the intravenous route. The drug candidate is an indenoisoquinoline derivative. The drug candidate acts by targeting topoisomerase I.
Quick View LMP-744 LOA Data
|Highest Development Stage|